Anteris Technologies Global Corp. (ASX:AVR)
Australia
· Delayed Price · Currency is AUD | Market Cap | 310.16M |
| Revenue (ttm) | 4.37M |
| Net Income (ttm) | -123.28M |
| Shares Out | 36.02M |
| EPS (ttm) | -6.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,165 |
| Average Volume | 10,653 |
| Open | 8.40 |
| Previous Close | 8.61 |
| Day's Range | 8.02 - 8.40 |
| 52-Week Range | 7.65 - 23.93 |
| Beta | 0.65 |
| RSI | 30.20 |
| Earnings Date | Mar 12, 2025 |
About ASX:AVR
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaf... [Read more]
Financial Performance
In 2024, ASX:AVR's revenue was $2.70 million, a decrease of -1.17% compared to the previous year's $2.74 million. Losses were -$76.29 million, 65.8% more than in 2023.
Financial numbers in USD Financial StatementsNews
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year
Anteris Reports 2024 Financial Results and Provides Corporate Update
EAGAN, Minn. and BRISBANE, Australia, March 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed ...
Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast
Tuesday, Medtronic Plc (NYSE: MDT) reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion . The medical device maker reported adjusted EPS of $1.39, beating the co...
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Barclays analyst initiates Positive coverage on ... Full story available on Benzinga.com
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC” or “Anteris”) is pleased to announce the closing of its initial public offering of 14,800,000 shares of i...
U.S. IPO Weekly Recap: ServiceTitan Shines In 3 IPO Week
Three IPOs and three SPACs listed this week - ServiceTitan, Anteris Technologies, NetClass, Mountain Lake Acquisition, Roman DBDR Acquisition II, and Jackson Acquisition II, respectively.
Anteris Technologies prices IPO at $6 per share
Anteris Technologies Global (AVR) priced IPO at $6.00 per share, trading on Nasdaq under ticker symbol AVR with proceeds for heart valve development.
Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC”) today announced the pricing of its initial public offering of 14,800,000 shares of its common stock (“Co...
Anteris Technologies (AVR) Plans $100 Million IPO on Nasdaq
Anteris Technologies (AVR) Plans $100 Million IPO on Nasdaq
Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC”) today announced that it has launched the roadshow for its proposed initial public offering of 14,800,000...
Anteris Technologies Targets $75 Million US IPO
Anteris Technologies Global Corp. Files Registration Statement for Proposed US Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC”) today announced that it has filed a Registration Statement on Form S-1 with the U.S. Securities and Exch...
Cardiac device maker Anteris Technologies files for $75M IPO
Australian cardiac device maker Anteris Technologies Global (AVR) has filed to raise $75M through a U.S. initial public offering. Read more here.
Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip™ Passes Animal Study
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of TAVR and the world's only balloon-expandable...
DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case
BRISBANE, Australia & MINNEAPOLIS--(BUSINESS WIRE)--Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR, OTC: ANTTY) reported today that DurAVR™ THV, a new class of biomimetic heart valve and ...
Anteris Technologies Commences American Depository Receipt Program
BRISBANE, Australia & MINNEAPOLIS--(BUSINESS WIRE)--Anteris Technologies Ltd, (Anteris or the Company) (ASX: AVR, OTC: ANTTY) reported today that it has established a sponsored Level 1 American Deposi...
Anteris Technologies Commences US Early Feasibility Study
BRISBANE, Australia & MINNEAPOLIS--(BUSINESS WIRE)--Anteris Technologies Ltd, (Anteris or the Company) (ASX: AVR, OTC: ANTTY) reported today that DurAVR™ Transcatheter Heart Valve (THV), a new class o...